NDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
FML FORTE (fluorometholone) by AbbVie is corticosteroid hormone receptor agonists [moa]. First approved in 1986.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FML FORTE is a fluorometholone ophthalmic suspension approved in 1986 for treating corneal opacity and epiphora. It is a potent corticosteroid that works by inhibiting inflammatory mediators and reducing edema, fibrin deposition, and leukocyte migration in ocular tissues. The mechanism involves induction of lipocortins, which suppress arachidonic acid release and downstream prostaglandin/leukotriene synthesis.
$0.887MPart D
LOE ApproachingDeclining
Product is in late-stage maturity with modest Part D utilization; marketing teams should focus on defending market share against generic/competitive erosion.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FML FORTE positions as a low-visibility, late-lifecycle product with minimal active hiring or career development momentum. Working on this asset offers defensive, cost-control experience but limited upside for career growth in a competitive ophthalmic market.
Company
Worked on FML FORTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.